X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with Cipla - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs CIPLA - Comparison Results

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES CIPLA ALKEM LABORATORIES/
CIPLA
 
P/E (TTM) x - 46.0 - View Chart
P/BV x 6.2 3.8 163.1% View Chart
Dividend Yield % 0.7 0.3 206.9%  

Financials

 ALKEM LABORATORIES   CIPLA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
CIPLA
Mar-17
ALKEM LABORATORIES/
CIPLA
5-Yr Chart
Click to enlarge
High Rs1,589622 255.5%   
Low Rs1,232458 268.8%   
Sales per share (Unadj.) Rs417.5181.9 229.6%  
Earnings per share (Unadj.) Rs56.312.9 437.4%  
Cash flow per share (Unadj.) Rs64.729.3 220.7%  
Dividends per share (Unadj.) Rs12.702.00 635.0%  
Dividend yield (eoy) %0.90.4 243.2%  
Book value per share (Unadj.) Rs292.9155.7 188.2%  
Shares outstanding (eoy) m119.57804.51 14.9%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.43.0 113.8%   
Avg P/E ratio x25.142.0 59.7%  
P/CF ratio (eoy) x21.818.4 118.3%  
Price / Book Value ratio x4.83.5 138.8%  
Dividend payout %22.615.5 145.2%   
Avg Mkt Cap Rs m168,653434,516 38.8%   
No. of employees `000NA23.0 0.0%   
Total wages/salary Rs m9,17126,338 34.8%   
Avg. sales/employee Rs ThNM6,349.1-  
Avg. wages/employee Rs ThNM1,143.0-  
Avg. net profit/employee Rs ThNM449.3-  
INCOME DATA
Net Sales Rs m49,915146,302 34.1%  
Other income Rs m1,6452,287 71.9%   
Total revenues Rs m51,561148,589 34.7%   
Gross profit Rs m8,48224,758 34.3%  
Depreciation Rs m1,00613,229 7.6%   
Interest Rs m6711,594 42.1%   
Profit before tax Rs m8,45112,222 69.1%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-70 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6061,798 89.3%   
Profit after tax Rs m6,73110,354 65.0%  
Gross profit margin %17.016.9 100.4%  
Effective tax rate %19.014.7 129.2%   
Net profit margin %13.57.1 190.5%  
BALANCE SHEET DATA
Current assets Rs m27,06287,370 31.0%   
Current liabilities Rs m15,32433,081 46.3%   
Net working cap to sales %23.537.1 63.4%  
Current ratio x1.82.6 66.9%  
Inventory Days Days6787 76.5%  
Debtors Days Days4162 66.3%  
Net fixed assets Rs m12,610111,567 11.3%   
Share capital Rs m2391,609 14.9%   
"Free" reserves Rs m34,490123,645 27.9%   
Net worth Rs m35,027125,254 28.0%   
Long term debt Rs m1,21236,454 3.3%   
Total assets Rs m54,387209,532 26.0%  
Interest coverage x13.68.7 156.9%   
Debt to equity ratio x00.3 11.9%  
Sales to assets ratio x0.90.7 131.4%   
Return on assets %13.65.7 238.7%  
Return on equity %19.28.3 232.5%  
Return on capital %24.98.5 292.4%  
Exports to sales %12.934.2 37.8%   
Imports to sales %3.18.3 37.0%   
Exports (fob) Rs m6,46150,050 12.9%   
Imports (cif) Rs m1,54012,203 12.6%   
Fx inflow Rs m6,56351,066 12.9%   
Fx outflow Rs m3,01217,678 17.0%   
Net fx Rs m3,55233,388 10.6%   
CASH FLOW
From Operations Rs m7,25923,824 30.5%  
From Investments Rs m1,864-13,127 -14.2%  
From Financial Activity Rs m-9,273-13,239 70.0%  
Net Cashflow Rs m-150-2,478 6.1%  

Share Holding

Indian Promoters % 66.9 16.0 418.1%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 33.1 12.2 271.3%  
FIIs % 0.0 23.7 -  
ADR/GDR % 0.0 1.1 -  
Free float % 0.0 26.2 -  
Shareholders   68,381 161,166 42.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   GLENMARK PHARMA  FULFORD INDIA  MERCK LTD  DIVIS LABORATORIES  UNICHEM LAB  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Tata Global Beverages Surges 8.3%(Closing)

Indian share markets snapped their losing streak of last week and finished the trading day on a strong note due to strong buying momentum in FMCG stocks, metal stocks and auto stocks.

Related Views on News

Cipla: Operating Margins Improve (Quarterly Results Update - Detailed)

Mar 8, 2017

Cipla has announced its results for the December quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Cipla: Weak Quarter, Positive Triggers Ahead (Quarterly Results Update - Detailed)

Sep 19, 2016

Cipla has announced its results for the June quarter (1QFY17) results. The company has reported a decline of 6.4% YoY in sales while profits were down by 43.7% YoY.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

Proxy Plays: A Smart Way to Bet on 'Off Limits' Companies(The 5 Minute Wrapup)

Aug 4, 2017

The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Aug 16, 2017 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS